×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMUX – immunic, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMUX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/26
06:40 am
imux
Immunic, Inc. to Participate in Investor Conference in December [Yahoo! Finance]
Medium
Report
Immunic, Inc. to Participate in Investor Conference in December [Yahoo! Finance]
11/26
06:30 am
imux
Immunic, Inc. to Participate in Investor Conference in December
Medium
Report
Immunic, Inc. to Participate in Investor Conference in December
11/25
08:02 am
imux
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.
11/15
08:03 am
imux
Insider Buys Additional US$100k In Immunic Stock [Yahoo! Finance]
Medium
Report
Insider Buys Additional US$100k In Immunic Stock [Yahoo! Finance]
11/13
05:33 pm
imux
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight [Yahoo! Finance]
Medium
Report
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight [Yahoo! Finance]
11/13
06:30 am
imux
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Medium
Report
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
11/11
11:15 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/11
10:00 am
imux
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
Medium
Report
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/18
04:36 pm
imux
Form 8-K IMMUNIC, INC. For: Dec 13
Low
Report
Form 8-K IMMUNIC, INC. For: Dec 13
12/9
08:31 am
imux
Form 4/A IMMUNIC, INC. For: Dec 04 Filed by: Nash Duane
Low
Report
Form 4/A IMMUNIC, INC. For: Dec 04 Filed by: Nash Duane
12/6
05:32 pm
imux
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Nash Duane
Medium
Report
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Nash Duane
12/6
05:32 pm
imux
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Muehler Andreas
Medium
Report
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Muehler Andreas
12/6
05:31 pm
imux
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Vitt Daniel
Medium
Report
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Vitt Daniel
12/6
05:31 pm
imux
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Tardio Jason
Medium
Report
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Tardio Jason
12/6
05:30 pm
imux
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Whaley Glenn
Medium
Report
Form 4 IMMUNIC, INC. For: Dec 04 Filed by: Whaley Glenn
11/14
05:34 pm
imux
Form SC 13G/A IMMUNIC, INC. Filed by: Avidity Partners Management LP
Medium
Report
Form SC 13G/A IMMUNIC, INC. Filed by: Avidity Partners Management LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/24
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston
90.9%
4/21 Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients 26.9%
3/25 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 26.7%
3/16 Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements 24.4%
12/11 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 22.8%
7/17 Form 8-K IMMUNIC, INC. For: Jul 15 12.0%
7/30 Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8 10.7%
6/4 Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2n? Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway 10.2%
4/20 Form 8-K IMMUNIC, INC. For: Apr 17 9.5%
2/1 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.3%
4/21 Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients 26.9%
3/25 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 26.7%
3/16 Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements 24.4%
12/11 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 22.8%
7/17 Form 8-K IMMUNIC, INC. For: Jul 15 12.0%
7/30 Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8 10.7%
6/4 Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2n? Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway 10.2%
4/20 Form 8-K IMMUNIC, INC. For: Apr 17 9.5%
2/1 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.3%
TOP News Decliners
3/25
Immunic and Cytosorbents among healthcare gainers; Immutep tops the losers [Seeking Alpha]
-25.6%
7/11 Immunic (NASDAQ: IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock. -20.1%
4/21 Immunic up 16% after hours on potential COVID-19 drug [Seeking Alpha] -16.5%
4/30 Form 4 IMMUNIC, INC. For: Apr 29 Filed by: Whaley Glenn -15.9%
4/22 Form 8-K IMMUNIC, INC. For: Apr 21 -13.8%
9/5 Immunic up 26% after hours on encouraging IMU-838 data [Seeking Alpha] -12.2%
7/16 Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer -12.0%
9/20 Form S-8 IMMUNIC, INC. -11.7%
11/19 Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips -10.0%
1/7 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -9.0%
7/11 Immunic (NASDAQ: IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock. -20.1%
4/21 Immunic up 16% after hours on potential COVID-19 drug [Seeking Alpha] -16.5%
4/30 Form 4 IMMUNIC, INC. For: Apr 29 Filed by: Whaley Glenn -15.9%
4/22 Form 8-K IMMUNIC, INC. For: Apr 21 -13.8%
9/5 Immunic up 26% after hours on encouraging IMU-838 data [Seeking Alpha] -12.2%
7/16 Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer -12.0%
9/20 Form S-8 IMMUNIC, INC. -11.7%
11/19 Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips -10.0%
1/7 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -9.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: